Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

The rollout marks a new chapter for men with prostate cancer, the most common cancer in Canadian men aside from skin cancer, ...

Rising brain tumor cases in India, with advanced imaging techniques and treatment options offering hope for better outcomes.

The results were similar across all income levels. Pet advocates say that shows a need for vets to adjust to address clients' ...

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer ...

Dr. Angela Jia discussed How Better Treatments and Better Selection Can Improve Patient Outcomes in Localized Prostate Cancer. Dr. Jia discussed two important abstracts presented during the session: ...

NCT05539430 is a Phase 1, open label, dose escalation, multicenter study to evaluate Claudin 18.2-targeting CAR-T cells (LB1908) in adult patients with unresectable, locally advanced or metastatic ...

Despite having no symptoms, Linda’s commitment to preventive care led to a life-saving lung cancer diagnosis. Learn why early ...

The image-guided therapy systems market is projected to grow at a CAGR of ~5% over the forecast period. Major factors driving ...